Are you Dr. Rutkowski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
30 S Cayuga Rd
Williamsville, NY 14221Phone+1 716-632-1088Fax+1 716-632-7842
Summary
- Dr. Piotr Rutkowski, MD is a board certified anesthesiologist in Williamsville, New York. He is currently licensed to practice medicine in New York, Florida, and Wisconsin. He is affiliated with KALEIDA Health.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Anesthesiology, 2010 - 2014
Jagiellonian University Medical CollegeClass of 2010
Certifications & Licensure
FL State Medical License 2022 - 2026
NY State Medical License 2015 - 2026
WI State Medical License 2011 - 2019- American Board of Anesthesiology Anesthesiology
Clinical Trials
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 2226 citationsDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V. Demidov, Thomas Jouary, Ralf Gutzmer
Lancet. 2012-07-28 - 377 citationsSafety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase ...Sant P. Chawla, Robert M. Henshaw, Leanne L. Seeger, Edwin Choy, Jean-Yves Blay
The Lancet. Oncology. 2013-08-01 - 65 citationsAn open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft...Patrick Schöffski, Douglas D. Adkins, Jean-Yves Blay, Thierry Gil, Anthony D. Elias
European Journal of Cancer. 2013-10-01
Press Mentions
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline UpdateNovember 10th, 2022- Immunotherapy Drug Benefits Patients with High-Risk Local MelanomasSeptember 18th, 2021
Dermatology Today and Tomorrow: From Symptom Control to Targeted TherapyDecember 18th, 2018
